Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mats, Någård"'
Autor:
Eric Wittbrodt, Jennifer Kim, Katarina Hedman, David C Wheeler, Jon Morris, Jonatan Hedberg, Henning Søndergaard, Cathy Gwynn, Alaster Allum, Hui-Lan Chung, Mats Någård, Gunilla Stjernlöf
Publikováno v:
BMJ Open, Vol 14, Iss 2 (2024)
Objectives Traditional potassium (K+) binders for treating hyperkalaemia are unpalatable and poorly tolerated. Newer K+ binders are reportedly better tolerated; however, no published data describe their palatability, a determinant of long-term adhere
Externí odkaz:
https://doaj.org/article/6ea9e4d26f6c4542a497f358e0a9408f
Autor:
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin, Steven Thomas, Kevin M Tuffy, Mats Någård, Mark T Esser, Katie Streicher, Taylor S Cohen, Anastasia A Aksyuk
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives The evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against emerging variants. Authentic virus neutralisation assays are cons
Externí odkaz:
https://doaj.org/article/d383527f067748c0a99eb961c96ff5ba
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Background and objectivePublished works have discussed the pharmacokinetic interactions of drugs with pregnancy, but none comprehensively identify all the approved United States Food and Drug Administration (FDA) and European Medicines Administration
Externí odkaz:
https://doaj.org/article/1ccdc4d5c0654780970b5c24d95953ea
Publikováno v:
Clinical Kidney Journal. 16:151-158
Background Sodium zirconium cyclosilicate (SZC) is an oral, highly selective potassium binder approved for the treatment of hyperkalaemia in adults. SZC may change the absorption of co-administered drugs that exhibit pH-dependent bioavailability. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a5eff4d984f58f19aa1eed13ab674d2
https://doi.org/10.1093/ckj/sfac205
https://doi.org/10.1093/ckj/sfac205
Publikováno v:
British Journal of Clinical Pharmacology. 88:1942-1946
Dapagliflozin is an inhibitor of human renal sodium-glucose cotransporter 2 (SGLT2), first approved for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f64ac807861f408acc4ac072356fdf81
https://doi.org/10.1111/bcp.15117
https://doi.org/10.1111/bcp.15117
Publikováno v:
Clinical Pharmacology in Drug Development. 11:348-357
Sodium zirconium cyclosilicate (SZC) is an effective potassium binder for patients with hyperkalemia. This single-center, open-label, phase I study (NCT03283267) characterized the pharmacodynamics and safety of SZC in Chinese individuals. Twenty-two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c438a75b60d99e710caf486b7a7b2b1
https://doi.org/10.1002/cpdd.1055
https://doi.org/10.1002/cpdd.1055
Autor:
Linda Sundström, Susanna Myhre, Monika Sundqvist, Andrea Ahnmark, William McCoull, Piotr Raubo, Sam D Groombridge, Magnus Polla, Ann-Christin Nyström, Lisbeth Kristensson, Mats Någård, Maria Sörhede Winzell
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0189060 (2017)
The mechanism behind the glucose lowering effect occurring after specific activation of GPR120 is not completely understood. In this study, a potent and selective GPR120 agonist was developed and its pharmacological properties were compared with the
Externí odkaz:
https://doaj.org/article/0ae7af91f78b4d848a82f18a857194db
Publikováno v:
Clinical Kidney Journal
Background Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is an oral potassium binder for the treatment of hyperkalemia in adults. SZC acts in the gastrointestinal tract and additionally binds hydrogen ions in acidic environments like the stomac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe8bd1779164cba5c66e72ec2ffb363
http://europepmc.org/articles/PMC8243284
http://europepmc.org/articles/PMC8243284
Publikováno v:
Clinical Kidney Journal
Background Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a potassium (K+) binder for treatment of hyperkalemia in adults. SZC binds K+ in exchange for sodium (Na+) or hydrogen (H+) in the gastrointestinal tract, conveying potential for syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c84c4594d683c4d866878098397032
http://europepmc.org/articles/PMC8323143
http://europepmc.org/articles/PMC8323143
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Sodium zirconium cyclosilicate (SZC) is a novel, oral, highly selective potassium binder approved for the treatment of hyperkalaemia (HK) in adults. As well as binding potassium, SZC binds hydrogen ions in the acidic environment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8cc9aed9153042b90e7750a4ff6f22c
https://doi.org/10.1093/ndt/gfac066.101
https://doi.org/10.1093/ndt/gfac066.101